Wednesday, August 31, 2022

Transfusion-dependent thalassaemia Market to Grow at a Substantial Growth Rate During the Forecast Period 2032 - DelveInsight | Key Companies - Celgene, bluebird bio, Sangamo Therapeutics

Transfusion-dependent thalassaemia Market to Grow at a Substantial Growth Rate During the Forecast Period 2032 -  DelveInsight | Key Companies - Celgene, bluebird bio, Sangamo Therapeutics
DelveInsight's "Transfusion-dependent thalassaemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Transfusion-dependent thalassaemia, historical and forecasted epidemiology as well as the Transfusion-dependent thalassaemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Transfusion-dependent thalassaemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Transfusion-dependent thalassaemia market dynamics. 

 

DelveInsight’sTransfusion-dependent thalassaemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Transfusion-dependent thalassaemia, historical and forecasted epidemiology as well as the Transfusion-dependent thalassaemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

 

Some of the key facts of the Transfusion-dependent thalassaemia Market Report: 

  • The Transfusion-dependent thalassaemia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)  
  • Secondary iron overload is the main issue with Transfusion-dependent thalassaemia; if handled, it can cause damage to target organs and even death 
  • Transfusion-dependent thalassaemia prevalence is rare in the United States 
  • The prevalence of symptomatic cases of Transfusion-dependent thalassaemia estimates to be approximately 1 in 100,000 individuals in the general population 
  • Key Transfusion-dependent thalassaemia Companies: Celgene, bluebird bio, Sangamo Therapeutics, Protagonist Therapeutics, Novartis Pharmaceuticals, Vertex Pharmaceuticals, and others 
  • Key Transfusion-dependent thalassaemia Therapies: PTG-300, BIVV003, Mitapivat, Deferasirox, Luspatercept, sofosbuvir/velpatasvir, Deferasirox dispersable tablet, and others 
  • Transfusion dependence happens when a patient needs an average of more than 2 units of blood transfused every 28 days for at least three months

 

Request a sample for the Transfusion-dependent thalassaemia Market Report 

 

Key benefits of the Transfusion-dependent thalassaemia Market report:

  1. Transfusion-dependent thalassaemia market report covers a descriptive overview and comprehensive insight of the Transfusion-dependent thalassaemia Epidemiology and Transfusion-dependent thalassaemia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Transfusion-dependent thalassaemia market report provides insights on the current and emerging therapies.
  3. Transfusion-dependent thalassaemia market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Transfusion-dependent thalassaemia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Transfusion-dependent thalassaemia market.

 

Discover more about therapies set to grab major Transfusion-dependent thalassaemia market share @ Transfusion-dependent thalassaemia market forecast 

 

Transfusion-dependent thalassaemia Overview

According to the severity of the phenotype, which is brought on by a wide range of mutations in a homozygous or compound heterozygous state, -thalassemias can be categorised clinically as transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT).

Reduced synthesis of the -globin chain, which causes a /-chain imbalance, the precipitation of -globin-heme complexes, and poor erythropoiesis are the hallmarks of -thalassemias. The disease's hallmarks—ineffective erythropoiesis, persistent hemolytic anaemia, and compensatory hematopoietic expansion—are connected to how severe the chain unbalance is. Numerous clinical variants of beta-thalassemia, such as haemoglobin E/beta-thalassemia, which results from beta-thalassemia coinheritance with haemoglobin E, have been reported. 

 

Transfusion-dependent thalassaemia Symptoms  

The Transfusion-dependent thalassaemia symptoms include -

  • Body Fatigue
  • Weakness
  • Shortness of breathing
  • Dizziness
  • Headaches
  • Nausea and vomiting

 

Transfusion-dependent thalassaemia Epidemiology Segmentation:

The Transfusion-dependent thalassaemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Transfusion-dependent thalassaemia
  • Prevalent Cases of Transfusion-dependent thalassaemia by severity
  • Gender-specific Prevalence of Transfusion-dependent thalassaemia
  • Diagnosed Cases of Episodic and Chronic Transfusion-dependent thalassaemia 

 

Transfusion-dependent thalassaemia Market  

The dynamics of the Transfusion-dependent thalassaemia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Mitapivat, Deferasirox, and others during the forecasted period 2019-2032.

 

Download the report to understand which factors are driving Transfusion-dependent thalassaemia epidemiology trends @ Transfusion-dependent thalassaemia Epidemiological Insights

 

Transfusion-dependent thalassaemia Therapies

  • PTG-300
  • BIVV003
  • Mitapivat 
  • Deferasirox
  • Luspatercept
  • sofosbuvir/velpatasvir
  • Deferasirox dispersable tablet

 

Transfusion-dependent thalassaemia Key Companies 

  • Celgene
  • bluebird bio
  • Sangamo Therapeutics 
  • Protagonist Therapeutics
  • Novartis Pharmaceuticals 
  • Vertex Pharmaceuticals 

 

Scope of the Transfusion-dependent thalassaemia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Transfusion-dependent thalassaemia Companies: Celgene, bluebird bio, Sangamo Therapeutics, Protagonist Therapeutics, Novartis Pharmaceuticals, Vertex Pharmaceuticals, and others
  • Key Transfusion-dependent thalassaemia Therapies: PTG-300, BIVV003, Mitapivat, Deferasirox, Luspatercept, sofosbuvir/velpatasvir, Deferasirox dispersable tablet, and others
  • Therapeutic Assessment: Transfusion-dependent thalassaemia current marketed and Transfusion-dependent thalassaemia emerging therapies
  • Migraine Market Dynamics:  Transfusion-dependent thalassaemia market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Transfusion-dependent thalassaemia  Market Access and Reimbursement 

 

Table of Contents 

1. Transfusion-dependent thalassaemia Market Report Introduction

2. Executive Summary for Transfusion-dependent thalassaemia

3. SWOT analysis of Transfusion-dependent thalassaemia

4. Transfusion-dependent thalassaemia Patient Share (%) Overview at a Glance

5. Transfusion-dependent thalassaemia Market Overview at a Glance

6. Transfusion-dependent thalassaemia Disease Background and Overview

7. Transfusion-dependent thalassaemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Transfusion-dependent thalassaemia 

9. Transfusion-dependent thalassaemia Current Treatment and Medical Practices

10. Transfusion-dependent thalassaemia Unmet Needs

11. Transfusion-dependent thalassaemia Emerging Therapies

12. Transfusion-dependent thalassaemia Market Outlook

13. Country-Wise Transfusion-dependent thalassaemia Market Analysis (2019–2032)

14. Transfusion-dependent thalassaemia Market Access and Reimbursement of Therapies

15. Transfusion-dependent thalassaemia Market drivers

16. Transfusion-dependent thalassaemia Market barriers

17.  Transfusion-dependent thalassaemia Appendix

18. Transfusion-dependent thalassaemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Transfusion-dependent thalassaemia treatment, visit @ Transfusion-dependent thalassaemia Medications

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com